Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus RENOVIST II.
DIONOSIL AQUEOUS vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent